DISEASE MODELING IN INFLAMMATORY BOWEL DISEASE (IBD) USING PATIENT-DERIVED EXPLANTS (PDE) REVEALS CHEMOKINES AS A RELEVANT TARGET OF JAK INHIBITION
Gastroenterology(2024)
摘要
Despite a recent explosion of approved drugs for IBD that primarily target cytokines and T-cell trafficking, therapeutic response rates remain low (30-50 %), underscoring the need for more efficacious treatments with fewer side effects. From a drug development perspective, it takes over 10 years for a new drug to reach the market with >90% attrition rates. The realization that drug testing in animal models does not always translate to humans, particularly for complex diseases of high heterogeneity like IBD, leaving a significant gap in pre-clinical drug evaluation.
更多查看译文
关键词
Therapies
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要